These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
351 related articles for article (PubMed ID: 15569425)
1. [Association between genetic polymorphisms of CYP2C19 and CYP2C9 and phenytoin serum concentration]. Huang Y; Yang JF; Qi XL; Wang YQ; Wang WZ; Chen B Zhonghua Yi Xue Za Zhi; 2004 Oct; 84(20):1686-9. PubMed ID: 15569425 [TBL] [Abstract][Full Text] [Related]
2. The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: studies in stereoselective hydroxylation and population pharmacokinetics. Mamiya K; Ieiri I; Shimamoto J; Yukawa E; Imai J; Ninomiya H; Yamada H; Otsubo K; Higuchi S; Tashiro N Epilepsia; 1998 Dec; 39(12):1317-23. PubMed ID: 9860067 [TBL] [Abstract][Full Text] [Related]
3. Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population. Scordo MG; Caputi AP; D'Arrigo C; Fava G; Spina E Pharmacol Res; 2004 Aug; 50(2):195-200. PubMed ID: 15177309 [TBL] [Abstract][Full Text] [Related]
4. Dosage recommendation of phenytoin for patients with epilepsy with different CYP2C9/CYP2C19 polymorphisms. Hung CC; Lin CJ; Chen CC; Chang CJ; Liou HH Ther Drug Monit; 2004 Oct; 26(5):534-40. PubMed ID: 15385837 [TBL] [Abstract][Full Text] [Related]
6. Influence of CYP2C9 genetic polymorphism and undernourishment on plasma-free phenytoin concentrations in epileptic patients. Ramasamy K; Narayan SK; Shewade DG; Chandrasekaran A Ther Drug Monit; 2010 Dec; 32(6):762-6. PubMed ID: 21068649 [TBL] [Abstract][Full Text] [Related]
7. Influence of the CYP2C9 AND CYP2C19 polymorphisms on phenytoin hydroxylation in healthy individuals from south India. Rosemary J; Surendiran A; Rajan S; Shashindran CH; Adithan C Indian J Med Res; 2006 May; 123(5):665-70. PubMed ID: 16873909 [TBL] [Abstract][Full Text] [Related]
9. CYP2C9, CYP2C19 and CYP2D6 allele frequencies in the Ashkenazi Jewish population. Scott SA; Edelmann L; Kornreich R; Erazo M; Desnick RJ Pharmacogenomics; 2007 Jul; 8(7):721-30. PubMed ID: 18240905 [TBL] [Abstract][Full Text] [Related]
10. Contributions of CYP2C9/CYP2C19 genotypes and drug interaction to the phenytoin treatment in the Korean epileptic patients in the clinical setting. Lee SY; Lee ST; Kim JW J Biochem Mol Biol; 2007 May; 40(3):448-52. PubMed ID: 17562299 [TBL] [Abstract][Full Text] [Related]
11. Effects of CYP2C19 and CYP2C9 genetic polymorphisms on the disposition of and blood glucose lowering response to tolbutamide in humans. Shon JH; Yoon YR; Kim KA; Lim YC; Lee KJ; Park JY; Cha IJ; Flockhart DA; Shin JG Pharmacogenetics; 2002 Mar; 12(2):111-9. PubMed ID: 11875365 [TBL] [Abstract][Full Text] [Related]
12. Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy. Odani A; Hashimoto Y; Otsuki Y; Uwai Y; Hattori H; Furusho K; Inui K Clin Pharmacol Ther; 1997 Sep; 62(3):287-92. PubMed ID: 9333104 [TBL] [Abstract][Full Text] [Related]
13. CYP2C9 and CYP2C19 genetic polymorphisms: frequencies in the south Indian population. Jose R; Chandrasekaran A; Sam SS; Gerard N; Chanolean S; Abraham BK; Satyanarayanamoorthy K; Peter A; Rajagopal K Fundam Clin Pharmacol; 2005 Feb; 19(1):101-5. PubMed ID: 15660966 [TBL] [Abstract][Full Text] [Related]
14. Association of galactose single-point test levels and phenytoin metabolic polymorphisms with gingival hyperplasia in patients receiving long-term phenytoin therapy. Lin CJ; Yen MF; Hu OY; Lin MS; Hsiong CH; Hung CC; Liou HH Pharmacotherapy; 2008 Jan; 28(1):35-41. PubMed ID: 18154472 [TBL] [Abstract][Full Text] [Related]
15. Neurological toxicity after phenytoin infusion in a pediatric patient with epilepsy: influence of CYP2C9, CYP2C19 and ABCB1 genetic polymorphisms. Dorado P; López-Torres E; Peñas-Lledó EM; Martínez-Antón J; Llerena A Pharmacogenomics J; 2013 Aug; 13(4):359-61. PubMed ID: 22641027 [TBL] [Abstract][Full Text] [Related]
16. Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Iranian population. Zand N; Tajik N; Moghaddam AS; Milanian I Clin Exp Pharmacol Physiol; 2007; 34(1-2):102-5. PubMed ID: 17201743 [TBL] [Abstract][Full Text] [Related]